Surveillance for Chronic Pancreatitis

Primary Surveillance Strategy

The European Society of Gastrointestinal Endoscopy recommends more frequent imaging (every 3-6 months) when concerning features develop, including new solid lesions, progressive ductal dilation, or unexplained clinical deterioration 1, 2

New-onset diabetes in a patient with established chronic pancreatitis should prompt immediate investigation for pancreatic cancer, as this represents a critical warning sign, according to the European Society of Gastrointestinal Endoscopy 2, 3
Solid lesions ≥5 mm detected on surveillance imaging require EUS with fine-needle aspiration (FNA) unless clearly identified as benign entities, as recommended by the European Society of Gastrointestinal Endoscopy 1, 3

Routine fasting blood glucose and/or HbA1c testing should be performed at each surveillance visit to detect new-onset diabetes, which occurs in 38-40% of chronic pancreatitis patients and may signal malignant transformation, according to the European Society of Gastrointestinal Endoscopy 2, 3
CA19-9 should be measured when worrisome imaging features appear, though it is not recommended for routine asymptomatic surveillance, as suggested by the European Society of Gastrointestinal Endoscopy 1, 3

Patients with hereditary pancreatitis (PRSS1 mutations) face dramatically elevated pancreatic cancer risk and require annual surveillance beginning at age 40 or 20 years after symptom onset, and warrant consideration for referral to specialized high-risk pancreatic surveillance programs, according to the European Society of Gastrointestinal Endoscopy 1, 3

Do not delay investigation of new-onset diabetes or unexplained symptoms by waiting for the next scheduled surveillance interval—these warrant immediate imaging, as recommended by the European Society of Gastrointestinal Endoscopy 2, 4
Do not perform surveillance at low-volume centers without access to specialized pancreatic surgery and multidisciplinary teams, as complex management decisions require expert interpretation, according to the European Society of Gastrointestinal Endoscopy 1, 3

For solid lesions ≥5 mm: Perform EUS-FNA and staging CT; refer for surgical evaluation if malignancy suspected, as recommended by the European Society of Gastrointestinal Endoscopy 1, 3
For main pancreatic duct dilation ≥10 mm: Obtain EUS-FNA to exclude malignancy; consider surgical consultation, according to the European Society of Gastrointestinal Endoscopy 1, 5
All pancreatic resections should be performed at specialty centers with high-volume pancreatic surgery experience and multidisciplinary teams, as recommended by the European Society of Gastrointestinal Endoscopy 1, 3